Johnson & Johnson: Company Report
One Johnson & Johnson Plaza New Brunswick NJ 08933 http://www.jnj.com/ - Phone: 732-5240400
- Fax: 732-2140332
- Industry : Drug Manufacturers - Major
- Employees : 117,000
- Exchange : NYSE
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.
| Stock Activity |
| fyi |
Last Price |
62.76 |
|
52 Week High |
65.95 |
|
52 Week Low |
46.25 |
|
Volume |
11.36 Mil |
|
Average Daily Volume (13wk) |
11.41 Mil |
| fyi |
50 Day Moving Average |
64.10 |
|
200 Day Moving Average |
59.97 |
|
Volatility (beta) |
0.56 |
| Stock Price History |
| | Change | Relative Strength |
| fyi |
Last 3 Months |
2.7% |
65 |
|
Last 6 Months |
2.7% |
52 |
| fyi |
Last 12 Months |
6.6% |
35 |
Historical charts
| Institutional Statistics |
|---|
| Analyst Consensus | Moderate Buy | | Institutional Ownership | 62.60% | More Analyst Ratings
Want to learn how to evaluate a stock? Walk through the steps using the Research Wizard. | advertisement
| Financials |
| | Last 12 Months | 5 Year Growth |
|
Sales |
61.9 Bil |
5.5% |
|
Income |
12.3 Bil |
8.4% |
|
Dividend Rate |
1.96 |
12.00% |
|
Dividend Yield |
3.14% |
2.50% |
More financials
| Fundamental Data |
|---|
| Debt/Equity Ratio | NA | | Gross Margin | 70.20% | | Net Profit Margin | 19.82% | | Total Shares Outstanding | 2.8 Bil | | Market Capitalization | 173.16 Bil | | Earnings/Share | 4.40 |
More financial ratios
| Earnings Estimates
|
| Qtr(3/10) EPS Estimate |
1.28 |
| FY(12/10) EPS Estimate |
4.92 |
| Current P/E |
14.20 |
| FY(12/11) EPS Estimate |
5.36 |
| Forward P/E |
11.71 |
| Next Earnings Release:
N/A | | More analyst estimates
|